Replies to post #207846 on Biotech Values

[DewDiligence]

ENTA—I am a bit surprised this news didn't give at least a little boost to ENTA given only two drugs are used so ENTA's royalties will be higher if approved. Am I missing something?

You're not missing anything—ENTA's tiered 10-20% royalties on G/P will be based on 50% of the regimen's overall price (compared to a 30% base for V-Pak and 45% for Technivie/Viekirax).

All told, ENTA has been pretty strong lately; the reason the stock didn't climb yesterday on the CERTAIN-1 (partial) data release is that investors already knew G/P was a very, very good HCV regimen from prior data releases—e.g. the data in #msg-126481635.